肿瘤药学
腫瘤藥學
종류약학
ANTI-TUMOR PHARMACY
2013年
4期
271-273,277
,共4页
蒋福平%陈力%邹勇德%雷厉
蔣福平%陳力%鄒勇德%雷厲
장복평%진력%추용덕%뢰려
甲状腺癌%MMP-13%表达%临床分期
甲狀腺癌%MMP-13%錶達%臨床分期
갑상선암%MMP-13%표체%림상분기
Thyroid carcinoma%MMP-13%Expression%Clinical stage
目的探讨 MMP-13在甲状腺癌组织中的表达及其与疾病分期的关系。方法采用免疫组化法检测62例甲状腺癌患者的癌组织以及癌旁正常组织中 MMP-13蛋白的表达水平,分析 MMP-13表达与甲状腺癌临床分期的关系。结果甲状腺癌组织中 MMP-13蛋白表达的阳性率为77.4%(48/62),显著高于癌旁正常组织的8.1%(5/62)(P<0.05);晚期(Ⅲ~Ⅳ期)甲状腺癌患者癌组织中 MMP-13蛋白表达的阳性率为94.7%(18/19),显著高于早期(Ⅰ~Ⅱ期)甲状腺癌患者的77.4%(48/62)(P<0.05)。结论甲状腺癌组织中 MMP-13蛋白的表达水平升高,MMP-13的高表达与甲状腺癌的疾病进展密切相关。
目的探討 MMP-13在甲狀腺癌組織中的錶達及其與疾病分期的關繫。方法採用免疫組化法檢測62例甲狀腺癌患者的癌組織以及癌徬正常組織中 MMP-13蛋白的錶達水平,分析 MMP-13錶達與甲狀腺癌臨床分期的關繫。結果甲狀腺癌組織中 MMP-13蛋白錶達的暘性率為77.4%(48/62),顯著高于癌徬正常組織的8.1%(5/62)(P<0.05);晚期(Ⅲ~Ⅳ期)甲狀腺癌患者癌組織中 MMP-13蛋白錶達的暘性率為94.7%(18/19),顯著高于早期(Ⅰ~Ⅱ期)甲狀腺癌患者的77.4%(48/62)(P<0.05)。結論甲狀腺癌組織中 MMP-13蛋白的錶達水平升高,MMP-13的高錶達與甲狀腺癌的疾病進展密切相關。
목적탐토 MMP-13재갑상선암조직중적표체급기여질병분기적관계。방법채용면역조화법검측62례갑상선암환자적암조직이급암방정상조직중 MMP-13단백적표체수평,분석 MMP-13표체여갑상선암림상분기적관계。결과갑상선암조직중 MMP-13단백표체적양성솔위77.4%(48/62),현저고우암방정상조직적8.1%(5/62)(P<0.05);만기(Ⅲ~Ⅳ기)갑상선암환자암조직중 MMP-13단백표체적양성솔위94.7%(18/19),현저고우조기(Ⅰ~Ⅱ기)갑상선암환자적77.4%(48/62)(P<0.05)。결론갑상선암조직중 MMP-13단백적표체수평승고,MMP-13적고표체여갑상선암적질병진전밀절상관。
Objective To investigate the expression of MMP-13 in thyroid carcinoma tissues and the relationship between MMP-13 expression and the clinical stages. Methods The expressions of MMP-13 protein were detected by immunohisto-chemical staining in thyroid carcinoma tissues and para-carcinoma tissues of 62 cases. The relationship between MMP-13 ex-pression and thyroid carcinoma stage was analyzed. Results The positive expression rate of MMP-13 protein in thyroid cancer tissue was 77.4% (48/62), significantly higher than the rate of para-carcinoma tissues which was 8.1% (5/62) (P<0.05). The MMP-13 protein expression rate in late stages (Ⅲ~Ⅳ) of thyroid carcinoma was 94.7% (18/19), significantly higher than the rate of early stages (Ⅰ~Ⅱ) which was 77.4% (48/62) (P<0.05). Conclusions The expression of MMP-13 protein significantly increased in thyroid carcinoma and it is closely related to the progression of thyroid carcinoma.